This implies that liraglutide and semaglutide may be beneficial for patients with type 2 diabetes, irrespective of their baseline BP (Diabetes Obesity and Metbolism)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?
This short review is focused on some open questions emerging from the effort to fully understand the link between COVID-19 and diabetes, mainly in the context of possible harmful or beneficial effects of commonly used drugs in patients with diabetes on the course of COVID-19 infection (Journal of Endocrinological Investigation)
Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes
HHS/DKA occurred mostly in T1D and younger patients. However, both also occurred in T2D, which is of great importance in the treatment of diabetes. Better education programmes are necessary to prevent decompensation and comorbidities (Acta Diabetologica)
The Australian response to the COVID-19 pandemic and diabetes – lessons learned
Once the COVID-19 pandemic is over, review of all the changes will be important, determining which should be permanently implemented. The learnings from COVID-19 should help prepare Australia for future pandemics or other major health crises (Diabetes Research and Clinical Practice)
Glucagon‐like peptide 1 receptor agonists and sodium glucose co‐transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta‐analysis
GLP‐1 RA/SGLT2i combination therapy seems to reduce HbA1c, body weight and systolic blood pressure without increasing the risk for severe hypoglycemia compared to either GLP‐1 RA or SGLT2i. No robust conclusions can be made regarding long‐term effectiveness or effect on cardiovascular outcomes (Diabetes, Obesity and Metabolism)
Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials
Guidelines for early-onset adult type 2 diabetes are extrapolated predominantly from evidence in older individuals. Strategies to support the participation of individuals with early-onset adult type 2 diabetes in future research are imperative to ensure guidelines for these high-risk individuals are evidence-based (Diabetologia)
Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
Use of SGLT2i improved cardiac function in diabetic patients, regardless of the presence of HF. The improvements were more prominent in HF patients, especially in those with HFrEF. These improvements in cardiac function would contribute to the clinical benefit of SGLT2i (Cardiovascular Diabetology)
Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID ‐19 pandemic
The aim of this manuscript is to comprehensively summarize the current knowledge on the antihyperglycemic properties of HCQ and to critically evaluate the potential risks and benefits related to HCQ use in patients with diabetes, even in light of the current pandemic scenario (Journal of Diabetes)
Comparative effectiveness of dapagliflozin vs DPP ‐4 inhibitors on a composite endpoint of HbA1c , body weight, and blood pressure reduction in the real world
T2D patients initiating the SGLT2i dapagliflozin had a greater probability of attaining a composite endpoint of clinically relevant reductions in HbA1c, body weight and SBP, compared to similar patients initiating a DPP‐4i in the same period and healthcare setting (Diabetes/Metabolism Research and Reviews)
Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race
These results support the HbA1c-lowering effectiveness of linagliptin across age, race, and renal function categories among a large real-world population of adults with T2DM (Diabetes Therapy)
Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020
Initiating insulin therapy, is recommended at or near the end of each treatment algorithm (JAMA)
CNS Regulation of Glucose Homeostasis: Role of the Leptin-Melanocortin System
The powerful antidiabetic actions of the CNS leptin-melanocortin system are capable of normalizing plasma glucose even in the absence of insulin and involve interactions of multiple neuronal populations and intracellular signaling pathways. Although the links between the CNS leptin-melanocortin system and its chronic effects on peripheral tissue glucose metabolism are still uncertain, they are independent of insulin action, activation of the autonomic nervous system, or the PTA axis (Current Diabetes Reports volume)
Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close
The administration of dipeptidyl peptidase‐4 inhibitors to specific groups of inpatients might be a safe and effective alternative to insulin (Diabetic Medicine)
Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility
The purpose of this review is to summarize the literature evidence that faces the pathophysiological mechanisms underlying bone fragility in T2DM patients (Journal of Diabetes Research)
Prevalence of Microvascular and Macrovascular Disease in the Glycemia Reduction Approaches in Diabetes – A Comparative Effectiveness (GRADE) Study Cohort
In the GRADE cohort with <10 years of T2D and a mean HbA1c of 8.0%, diabetes complications were present in a substantial fraction of participants, more so than might otherwise have been expected (Diabetes Research and Clinical Practice)
Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis
At admission, combining procalcitonin and presence of fever may be of value to distinguish ketoacidosis patients with and without proven bacterial infection, admitted in intensive care unit (Annals of Intensive Care)
Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a cohort study in people with diabetes
Deaths in people with diabetes in England have more than doubled during the COVID-19 epidemic. Hyperglycaemia and obesity in both Type 1 and Type 2 diabetes were independently associated with increased COVID-19 mortality. Risk factor control could diminish the impact of COVID-19 in diabetes (NHS England)
Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a whole population study
This nationwide analysis in England demonstrates that all types of diabetes are independently associated with a significant increased risk of in-hospital death with COVID-19 (NHS England)
The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes
In persons with T2DM, intensive SBP lowering decreased the risk of cardiovascular composite end point irrespective of baseline DBP in the setting of standard glycemic control. Hence, low baseline DBP should not be an impediment to intensive SBP lowering in patients with T2DM treated with guidelines recommending standard glycemic control (Diabetes Care)
Outcomes in Patients With Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control?
Insulin infusion may be an effective method for achieving glycemic targets and improving outcomes in patients with Covid-19 (Diabetes Care)
- 1
- 2
- 3
- …
- 198
- Next Page »
Glycosmedia is also available as an App: